Half-Sandwich Ru(II) Complexes Bearing 2-(2-quinoly)benzimidazoles with Anticancer Activity
Biointerface Research in Applied Chemistry · 15.08.2024 · 14 (4) · 82
DOI: 10.33263//briac144.082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biointerface Research in Applied Chemistry, online erschienen am 15.08.2024. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
In this article, cytotoxic and apoptotic properties of previously synthesized and characterized four different half‐sandwich ruthenium (II) complexes (C1-C4) with 2-(2-quinoly) benzimidazole frameworks (L1-L5) were described. These Ru (II) complexes (C1-C4) had strong cytotoxic activity towards the human glioblastoma (U373) cancer cell line with low toxicity to the non-cancerous human embryonic kidney (HEK293) cell line. Mechanistic studies revealed that all complexes caused apoptosis induction by activating caspases with upregulation of Bax and downregulation of Bcl-2. Our results indicate that ruthenium (II) complexes with 2-(2-quinoly) benzimidazole frameworks, especially C1 and C4, had a higher cytotoxic and apoptotic activity in human glioblastoma cells, and they should be further evaluated in detail for its anticancer properties as a new therapeutical strategy for glioblastoma.
Zitieren
APA
(2024). Half-Sandwich Ru(II) Complexes Bearing 2-(2-quinoly)benzimidazoles with Anticancer Activity. Biointerface Research in Applied Chemistry, 14(4), 82. https://doi.org/10.33263//briac144.082
Vancouver
Half-Sandwich Ru(II) Complexes Bearing 2-(2-quinoly)benzimidazoles with Anticancer Activity. Biointerface Research in Applied Chemistry. 2024;14(4):82. doi:10.33263//briac144.082
BibTeX
@article{euvimed2024,
title = {Half-Sandwich Ru(II) Complexes Bearing 2-(2-quinoly)benzimidazoles with Anticancer Activity},
journal = {Biointerface Research in Applied Chemistry},
year = {2024},
volume = {14},
number = {4},
pages = {82},
doi = {10.33263//briac144.082}
}
EUVIMED